Welcome to our dedicated page for MediWound Ltd. SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MediWound Ltd. SEC filings document a foreign private issuer focused on enzymatic therapeutics for tissue repair. Its Form 20-F annual reports and Form 6-K current reports cover operating and financial results, clinical and regulatory disclosures for NexoBrid and EscharEx, material-event updates, and registration-statement information tied to Form S-8 and Form F-3 filings.
The company’s filings also record governance and capital-structure matters, including annual and extraordinary shareholder meeting materials, proxy statements, board elections, ordinary share voting mechanics, and share incentive plan approvals under Israeli corporate governance requirements. Other disclosures address distribution and procurement-related developments for NexoBrid, risk factors, material agreements, and shareholder voting results.
MediWound Ltd. (MDWD) director Samuel Rubinstein reported offsetting indirect trades in ordinary shares held by his spouse on September 1, 2026, selling 525 shares at $12.72 and purchasing 525 shares at $12.62, resulting in no net change in share count. The filing also lists existing equity holdings, including stock options to acquire ordinary shares with exercise prices of $9.64, $12.73, $18.54 and $17.60, covering 7,200; 7,542; 5,600; and 6,250 underlying shares, respectively, plus ordinary shares underlying RSUs that vest one year after a March 4, 2026 grant. Several rows are explicitly described as informational only, with no transactions effected, and no Rule 10b5-1 trading plan is reported.
MediWound Ltd. (MDWD) reported insider option exercises and share sales by Shmuel Hess, COO & Chief Commercial Officer. On August 26–27, 2026 he exercised 16,000 stock options at an exercise price of $8.1292 per share on a net (cashless) basis, receiving 5,823 ordinary shares that were all sold the same days in open-market transactions totaling 5,823 shares at prices between $12.72 and $13.126 per share. He continues to hold several option grants over additional ordinary shares with exercise prices between $12.729 and $18.54 and expirations from 2034 to 2036.
MediWound Ltd. (MDWD) is the issuer of ordinary shares that Shmulik Hess intends to sell under Rule 144. The notice covers a proposed sale of 3,958 ordinary shares, with an aggregate market value of $50,266.60, through Oppenheimer & Co. Inc. on Nasdaq. MediWound reports 12,835,148 ordinary shares outstanding as of the notice date context. The filing also notes that during the prior three months, Hess sold 1,865 ordinary shares for $24,245.00. The shares to be sold on August 27, 2026 were acquired upon exercise of employee stock options for cash.
MediWound Ltd. (MDWD) reports that HOLD Alapkezelo Zrt., a Hungarian investment manager, has filed Amendment No. 2 to its Schedule 13G/A, updating its ownership in the company. HOLD Alapkezelo Zrt. is deemed to beneficially own 1,348,323 common shares of MediWound.
This position represents 10.4% of MediWound’s common stock, based on 12,910,278 shares outstanding as of June 30, 2026, as referenced from MediWound’s Form 6-K filed on August 13, 2026. HOLD Alapkezelo Zrt. reports sole voting and sole dispositive power over all 1,348,323 shares and no shared voting or dispositive power.
T. Rowe Price Associates, Inc. reported beneficial ownership of 641,075 shares of Mediwound Ltd. common stock, representing 5.0% of the class as of June 30, 2026. The firm has sole voting power over 638,398 shares and sole dispositive power over 641,075 shares, with no shared voting or dispositive power.
The shares relate to Mediwound’s common stock with CUSIP M68830112. T. Rowe Price Associates states that this report should not be construed as an admission that it is the beneficial owner of these securities, and it expressly denies such beneficial ownership.
MediWound Ltd. reported second quarter and first-half 2026 results, showing continued investment in its burn and wound-care portfolio alongside weaker revenue. Total revenues were $3.1 million for the quarter and $4.6 million for the six months ended June 30, 2026, down from $5.7 million and $9.7 million, respectively, a year earlier, mainly due to lower development services revenue. The company reaffirmed its full-year 2026 revenue guidance of $24–26 million.
The operating loss widened to $9.5 million in the quarter and $17.4 million for the first half, compared with $5.7 million and $10.9 million in the prior-year periods, driven by higher research and development, selling, and general and administrative expenses. Net loss nonetheless narrowed to $7.4 million for the quarter and $10.3 million for the half, helped by $7.1 million of net financing income largely related to warrant revaluation.
Cash and bank deposits totaled $35.8 million as of June 30, 2026, and management believes this will fund operations and capital expenditures for at least twelve months from the financial statement approval date. The EscharEx® Phase III VALUE trial is progressing, with interim assessment and enrollment completion expected by the end of the first quarter of 2027. A new Master Services Agreement with Vericel, tied to a ten-year BARDA contract of up to $197 million, is expected to generate NexoBrid-related development revenue in the second half of 2026.
MediWound Ltd. director Nachum Shamir reported buying 6,000 ordinary shares in the open market. The Form 4 shows two purchase transactions on June 3, 2026, involving 5,825 shares at $14.00 per share and 175 shares at $13.975 per share.
Following these purchases, Shamir directly holds 49,990 ordinary shares. He also has 1,200 ordinary shares underlying RSUs that were granted on March 4, 2026 and vest in full one year after the grant date. In addition, he holds several stock option grants and Series A warrants over ordinary shares with exercise prices between $11.8850 and $18.5400, and Series A warrants exercisable at $13.4750 per share through November 28, 2026.
MediWound Ltd. director David Morton Fox reported open-market purchases of a total of 3,537 ordinary shares on June 1, 2026, at prices between $13.995 and $14.23 per share. Other rows in the filing reflect existing holdings only, with no transactions in those securities.
He also holds several equity incentives, including stock options over 6,250 ordinary shares at an exercise price of $17.6000 expiring on March 4, 2036, and Series A warrants over 6,534 ordinary shares at an exercise price of $13.4750 expiring on November 28, 2026. Footnotes state that certain RSUs and options granted on March 4, 2026 vest 100% on the one-year anniversary of that grant date.
MediWound Ltd. director Samuel Rubinstein reported a small open-market purchase of 150 Ordinary Shares of MediWound on May 29, 2026 at $14.33 per share. After this trade, he directly holds 2,993 Ordinary Shares and indirectly holds 525 Ordinary Shares through his spouse.
He also holds several stock option awards giving rights to buy additional Ordinary Shares at exercise prices between $9.64 and $18.54, with expirations from 2033 to 2036. Footnotes clarify that certain ordinary share and option holdings reflect previously granted RSUs and options included for informational purposes, with no transactions occurring in those rows.
MediWound Ltd. reported first quarter 2026 revenue of $1.5 million, down from $4.0 million in the first quarter of 2025, as it increased investment in its pipeline. The company reaffirmed full‑year 2026 revenue guidance of $24–26 million.
For the quarter ended March 31, 2026, MediWound recorded an operating loss of $8.0 million and a net loss of $3.0 million, compared with a net loss of $0.7 million a year earlier, driven mainly by higher research and development spending.
The global Phase III VALUE trial of EscharEx in venous leg ulcers is ongoing, with enrollment progressing more gradually than anticipated; an interim assessment and enrollment completion are expected by the end of the first quarter of 2027. For NexoBrid, a BARDA contract awarded to Vericel and other government and military initiatives are expected to support revenue growth in the second half of 2026.
As of March 31, 2026, MediWound held $44.6 million in cash, cash equivalents and short‑term bank deposits and reported Adjusted EBITDA of -$7.0 million for the quarter, reflecting continued operating losses as it advances late‑stage programs.